Agomelatine
(asked on 15th October 2019) - View Source
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care what steps he is taking to ensure the adequacy of the supply of Agomelatine in the event that the UK leaves the EU on 31 October 2019 without a deal.
The Department is doing everything appropriate to prepare for leaving the European Union. We want to reassure patients that our plans should ensure the uninterrupted supply of medicines and medical products, including those for use in the treatment of depression, once we have left the EU.
The Department, as part of our EU exit preparations, is implementing a multi-layered approach to mitigate potential disruption to supply, which consists of stockpiling where possible, securing freight capacity, changing or clarifying regulatory requirements, procuring additional warehousing, working closely with industry to improve trader readiness and putting in place the National Supply Disruption Response to manage potential shortages. Further details can be found at the following link:
There is no evidence of any supply shortages being related to leaving the European Union. We are aware that one supplier of generic agomelatine 25mg tablets discontinued supplies in July 2019. However, we can confirm that supplies of agomelatine 25mg tablets are currently available from several other suppliers in volumes that are sufficient to meet normal United Kingdom demand. All patients who require agomelatine should be able to obtain a supply from their pharmacy.